Chiglitazar: First Approval

Chiglitazar (Bilessglu(R)) is an orally administered, non-thiazolidinedione small-molecule agonist of alpha, delta and gamma peroxisome proliferator-activated receptors (PPARs) being developed by Chipscreen Biosciences for the treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis. In October 2021, chiglitazar was approved in China for use as an adjunct to diet and exercise to improve glycaemic control in adult patients with T2D. The drug is also in phase 2 clinical development in China for the treatment of non-alcoholic steatohepatitis. This article summarizes the milestones in the development of chiglitazar leading to this first approval for the treatment of T2D.

Automated summary

Chiglitazar, an orally administered small-molecule agonist of PPARs, has been approved in China for the treatment of type 2 diabetes and is undergoing phase 2 clinical development for non-alcoholic steatohepatitis.